A relatively new class of drugscalled sodium-glucose cotransporter-2 (SGLT2) inhibitorshave proven beneficial for both diabetic and non-diabetic CKD and appear poised to become a mainstay treatment
Change history 01 March 2025 The original online version of this article was revised: The funding statement "Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB)." should be removed, as this paper was published under the subscription method rather than open access
Evite o uso em conjunto com estimulantes fortes e no ultrapasse a dose recomendada
Adding more water spreads that peptide through a larger volume, so each microgram sits in more millilitres and more units of solution
Por tanto, se recomienda tomar ambos suplementos a diferentes horas, para asegurar un efecto ptimo
Adeoye O, Olawumi J, Opeyemi A, Christiania O